SSD (silver sulfadiazine) by Dr. Reddy's Laboratories is clinical pharmacology silver sulfadiazine has broad antimicrobial activity. First approved in 1982.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
Silver sulfadiazine is a topical antimicrobial cream combining silver and sulfadiazine for broad-spectrum bactericidal activity against gram-positive, gram-negative bacteria, and yeast. It acts on bacterial cell walls to inhibit resistant organisms and is superior to sulfadiazine alone. This product is indicated for burn wound care and other topical infections requiring antimicrobial prophylaxis.
Mature product in LOE phase with declining Part D claims (222,662 in 2023); brand team likely focused on retention and transition planning rather than growth initiatives.
CLINICAL PHARMACOLOGY Silver sulfadiazine has broad antimicrobial activity. It is bactericidal for many gram-negative and gram-positive bacteria as well as being effective against yeast. Results from in vitro testing are listed below. Sufficient data have been obtained to demonstrate that silver…
Sulfonamide Antibacterial
Worked on SSD at Dr. Reddy's Laboratories? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study of Suzetrigine (SUZ) Spray-dried Dispersion (SSD) in Healthy Adult Panelists
Rifaximin SSD in Dementia Trial
A Study to Compare the Pharmacokinetics (PK) of Depemokimab When Delivered With a Safety Syringe Device (SSD) or an Autoinjector in Healthy Adult Participants
Interaural Frequency and Loudness Mismatch in SSD CI Users
Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on silver sulfadiazine offers limited career growth due to its LOE status and minimal linked job openings (0 identified), making it a consolidation or maintenance-phase assignment rather than a high-visibility launch or growth opportunity. Professionals on this product typically focus on operational efficiency, regulatory compliance, and managed transition to generic competition—valuable skills but with lower promotional visibility than growth-stage brands.